Canaccord Provides Input Into Jazz’s Patent Fight Against Flamel On Xyrem
In a research report issued Friday, Canaccord Genuity analyst John Newman reiterated a Buy rating on Jazz Pharmaceuticals (NASDAQ:JAZZ) with a $163 price target, as Flamel (NASDAQ:FLML) management stated the company earlier this year that it would eventually file its sodium oxybate formulation via the 505(b)(2) paragraph IV pathway, which would reference Jazz’s Xyrem NDA and certify against Jazz’s orange book listed patents.
Newman wrote, “Flamel’s strategy for its version of Xyrem is to file a 505(b)(2) paragraph IV, which would trigger a lawsuit from Jazz and a 30-month stay. The only way for Flamel to avoid litigation would be to file a full NDA, not referencing any of Jazz’s prior data, which does not seem to be its strategy. Given Jazz’s patents, we expect strong protection vs Flamel.” The analyst continued, “Jazz has already started a Phase 1 PK/PD/safety trial for JZP-386, with data expected by YE14. Flamel’s formulation won’t start registration trials until YE15, giving JAZZ a significant head start in time to drug launch and commercialization. Flamel’s once-nightly sodium oxybate seems attractive vs the 2x nightly formulation of Xyrem, but JZP-386 is also a once-nightly formulation.”
According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst John Newman has a total average return of -4.5% and a 43.5% success rate. Newman has a 13.5% average return when recommending JAZZ, and is ranked #2931 out of 3315 analysts.